Overview: TP53 TestIntroduction: The TP53 Test tests for TP53 gene mutations to diagnose cancers like breast or colon cancer, helping guide targeted therapy for abnormal cell growth. Affecting 1 in 100 people with cancer, TP53 mutations pose diagnostic challenges due to tumor heterogeneity. Following 2023 National Comprehensive Cancer Network (NCCN) guidelines, it uses PCR/sequencing for high accuracy, supporting molecular pathology screening. This test is vital for diagnosis, treatment planning, and improving outcomes in oncology.
Other Names: TP53 Mutation Test, Cancer Gene Assay.
FDA Status: Laboratory-developed test (LDT), meeting pathology standards for diagnostic reliability.
Historical Milestone: TP53 testing began in the 1980s with research by Baker, who identified the mutation. PCR/sequencing advancements by Illumina improved detection, surpassing earlier Sanger methods.
Purpose: Detects TP53 mutation status to diagnose cancers like breast or colon cancer, guides targeted therapy, and evaluates patients with cancer history, aiming to manage disease.
Test Parameters: TP53 mutation status
Pretest Condition: Tissue biopsy required. Collect tissue or whole blood. Report history of cancer.
Specimen: Tissue (FFPE, 0.5-2 cma³), Whole Blood (EDTA, 3-5 mL); Tissue in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: 1 month
Medical History: Document cancer history. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., metastasis), and sample collection risks.
Procedural Considerations: Uses PCR/sequencing to detect mutations, requiring labs with thermal cyclers. Results available in 5-7 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Positive mutation confirms cancer risk, guiding therapy. Early treatment might improve survival, while untreated cases lead to death. Normal results may require other tests.
Specialist Consultation: Consult an oncologist for interpretation.
Additional Supporting Tests: Biopsy, imaging, or genetic panel to confirm diagnosis.
Test Limitations: Specific to TP53; correlation with clinical status needed. False negatives possible with other mutations.
References: NCCN Guidelines, 2023; Science, Baker SJ, 2022.
